Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

8.250 +0.190 (+2.36%)
Streaming Delayed Price Updated: 2:05 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
3 Cash-Burning Stocks We Think Twice About
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh... 
Via StockStory
Topics Economy
News headline image
3 of Wall Street’s Favorite Stocks We Think Twice About
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
2 High-Flying Stocks to Consider Right Now and 1 That Underwhelm
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
News headline image
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ... 
Via StockStory
Topics Economy Stocks
NeoGenomics Inc (NASDAQ:NEO) Beats Q4 Earnings Estimates and Provides 2026 Guidance ↗
Via Chartmill
News headline image
3 Reasons to Avoid NEO and 1 Stock to Buy Instead
What a fantastic six months it’s been for NeoGenomics. Shares of the company have skyrocketed 48.3%, hitting $9.94. This was partly thanks to its solid quarterly results, and the performance may have... 
Via StockStory
News headline image
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call
NeoGenomics’ fourth quarter results were met with a negative market reaction, despite revenue and non-GAAP earnings per share surpassing Wall Street’s expectations. Management attributed the quarter’s... 
Via StockStory
Topics Earnings
News headline image
Why NeoGenomics (NEO) Shares Are Falling Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 10.1% in the afternoon session after the company reported fourth-quarter results that beat expectations but issued a... 
Via StockStory
Topics Artificial Intelligence
News headline image
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.6% year on year to $190.2 million. The company... 
Via StockStory
News headline image
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript ↗
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat Estimates
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.6% year on year to $190.2 million. The company... 
Via StockStory
Topics Earnings
News headline image
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be announcing earnings results this Tuesday before the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
1 Stock Under $50 Worth Your Attention and 2 We Brush Off
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
News headline image
3 Cash-Burning Stocks with Warning Signs
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. 
Via StockStory
Topics Electric Vehicles
News headline image
3 Russell 2000 Stocks We Think Twice About
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
News headline image
3 Stocks Under $50 We Steer Clear Of
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
News headline image
Testing & Diagnostics Services Stocks Q3 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how NeoGenomics (NASDAQ:NEO) and... 
Via StockStory
News headline image
3 Overrated Stocks That Concern Us
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
News headline image
1 Cash-Burning Stock to Research Further and 2 We Brush Off
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. 
Via StockStory
Topics Retirement
News headline image
NeoGenomics, Fortrea, and Acadia Healthcare Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Artificial Intelligence Economy Stocks
News headline image
1 High-Flying Stock on Our Buy List and 2 We Find Risky
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
News headline image
1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
Earnings Scheduled For November 14, 2025 ↗
 
Via Benzinga
News headline image
3 Volatile Stocks We Keep Off Our Radar
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
News headline image
The Top 5 Analyst Questions From NeoGenomics’s Q3 Earnings Call
NeoGenomics’ third quarter results were met with a negative market reaction, as shares declined following the announcement. Management attributed the quarter’s performance to robust growth in clinical... 
Via StockStory
Topics Earnings
News headline image
NeoGenomics (NEO): Buy, Sell, or Hold Post Q3 Earnings?
NeoGenomics trades at $9.78 per share and has stayed right on track with the overall market, gaining 24.7% over the last six months. At the same time, the S&P 500 has returned 21.3%. 
Via StockStory
Topics Stocks
News headline image
NEO Q3 Deep Dive: Clinical Volume Gains and New Product Launches Shape Outlook
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 11.9% year on year to $187.8 million. The company... 
Via StockStory
News headline image
NeoGenomics (NEO) Q3 2025 Earnings Call Transcript ↗
NeoGenomics (NEO) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Why NeoGenomics (NEO) Stock Is Trading Up Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 1.1% in the morning session after it reported third-quarter 2025 results where revenue beat Wall Street's expectations. 
Via StockStory
Topics World Trade
News headline image
NeoGenomics Inc (NASDAQ:NEO) Surpasses Q3 Revenue Estimates as Clinical Testing Drives Growth ↗
NeoGenomics Q3 2025 earnings beat revenue estimates with 11.9% growth. Clinical test volume surged 15%, driving a 5.4% pre-market stock rally. 
Via Chartmill
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.